- Zacks Small Cap Research•2 days ago
By Grant Zeng, CFA OBB:SNGX On July 25, 2016, Soligenix (OBB:SNGX) announced that the company has been granted additional funding from the Biomedical Advanced Research and Development Authority (BARDA) ...
- Zacks Small Cap Research•8 days ago
On July 18, 2016, Soligenix (SNGX) announced positive preliminary proof-of-concept results from a heat stable subunit Ebola vaccine. This is a collaboration with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawaiʻi at Mānoa (UH Mānoa) and Hawaii Biotech, Inc. (HBI). Soligenix’s ThermoVax Technology is used in this collaboration and has identified a formulation that enhances the physical stability of the protein and may be dose sparing.
|52wk Range||0.44 - 1.80|
|Day's Range||0.61 - 0.65|
|Avg Vol (3m)||88,539|
As of 3:32 PM EDT. Market closed.